Pavan Kasi Bendapudi, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Purpura, Thrombotic Thrombocytopenic | 14 | 2024 | 131 | 6.450 |
Why?
|
Thrombotic Microangiopathies | 8 | 2023 | 124 | 3.190 |
Why?
|
Purpura Fulminans | 4 | 2024 | 21 | 2.840 |
Why?
|
Plasma Exchange | 8 | 2024 | 159 | 2.230 |
Why?
|
Biological Specimen Banks | 2 | 2024 | 789 | 1.240 |
Why?
|
Factor XII | 2 | 2024 | 20 | 0.950 |
Why?
|
Hematologic Agents | 1 | 2024 | 39 | 0.910 |
Why?
|
Prothrombin | 1 | 2024 | 194 | 0.890 |
Why?
|
Disseminated Intravascular Coagulation | 2 | 2022 | 187 | 0.880 |
Why?
|
Thrombosis | 11 | 2024 | 2956 | 0.880 |
Why?
|
Factor V | 1 | 2024 | 168 | 0.880 |
Why?
|
Ursidae | 1 | 2023 | 26 | 0.870 |
Why?
|
Erythroblastosis, Fetal | 1 | 2023 | 62 | 0.870 |
Why?
|
Hematologic Diseases | 2 | 2023 | 498 | 0.830 |
Why?
|
Neisseria meningitidis, Serogroup C | 1 | 2021 | 11 | 0.760 |
Why?
|
Protein C | 2 | 2018 | 134 | 0.750 |
Why?
|
Factor V Deficiency | 1 | 2021 | 10 | 0.750 |
Why?
|
Meningococcal Infections | 1 | 2021 | 78 | 0.720 |
Why?
|
ADAM Proteins | 2 | 2024 | 243 | 0.650 |
Why?
|
Thrombomodulin | 1 | 2018 | 107 | 0.600 |
Why?
|
Heterozygote | 1 | 2024 | 2798 | 0.570 |
Why?
|
Venous Thrombosis | 2 | 2023 | 1321 | 0.550 |
Why?
|
Hemostasis | 2 | 2017 | 468 | 0.500 |
Why?
|
Blood Coagulation | 6 | 2024 | 1161 | 0.480 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2019 | 246 | 0.480 |
Why?
|
Anticoagulants | 6 | 2022 | 4850 | 0.460 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 1669 | 0.430 |
Why?
|
Warfarin | 1 | 2022 | 1493 | 0.430 |
Why?
|
Sepsis | 2 | 2024 | 2609 | 0.390 |
Why?
|
Protein Disulfide-Isomerases | 3 | 2018 | 211 | 0.360 |
Why?
|
Blood Coagulation Factors | 2 | 2024 | 371 | 0.350 |
Why?
|
Immunologic Factors | 1 | 2019 | 1597 | 0.340 |
Why?
|
Disease Management | 1 | 2020 | 2537 | 0.320 |
Why?
|
Recombinant Proteins | 5 | 2024 | 6512 | 0.290 |
Why?
|
Thrombin | 3 | 2024 | 600 | 0.270 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 18065 | 0.250 |
Why?
|
Plasma Kallikrein | 1 | 2024 | 21 | 0.230 |
Why?
|
Humans | 46 | 2024 | 768887 | 0.230 |
Why?
|
HSP47 Heat-Shock Proteins | 1 | 2023 | 4 | 0.220 |
Why?
|
Hemagglutinins | 1 | 2023 | 111 | 0.220 |
Why?
|
Receptors, Complement | 1 | 2024 | 254 | 0.220 |
Why?
|
Erythrocytes, Abnormal | 1 | 2023 | 121 | 0.210 |
Why?
|
Blood Group Incompatibility | 1 | 2023 | 134 | 0.210 |
Why?
|
Antigen-Antibody Complex | 1 | 2024 | 513 | 0.200 |
Why?
|
Angioedemas, Hereditary | 1 | 2023 | 91 | 0.200 |
Why?
|
Hemorrhage | 4 | 2022 | 3465 | 0.190 |
Why?
|
Hemolysis | 1 | 2023 | 417 | 0.190 |
Why?
|
Purpura, Thrombocytopenic | 1 | 2021 | 42 | 0.190 |
Why?
|
ABO Blood-Group System | 1 | 2023 | 381 | 0.180 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15955 | 0.180 |
Why?
|
Urogenital Abnormalities | 1 | 2023 | 255 | 0.180 |
Why?
|
Urinary Tract | 1 | 2023 | 305 | 0.170 |
Why?
|
Adult | 17 | 2024 | 223818 | 0.170 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2021 | 147 | 0.170 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2024 | 667 | 0.170 |
Why?
|
Lasers | 2 | 2021 | 952 | 0.170 |
Why?
|
Capnocytophaga | 1 | 2018 | 26 | 0.160 |
Why?
|
Blood Proteins | 1 | 2024 | 1191 | 0.160 |
Why?
|
Venous Thromboembolism | 2 | 2024 | 1880 | 0.160 |
Why?
|
Abruptio Placentae | 1 | 2020 | 116 | 0.160 |
Why?
|
Shock | 1 | 2021 | 316 | 0.150 |
Why?
|
Multiple Organ Failure | 1 | 2021 | 387 | 0.150 |
Why?
|
Factor XI Deficiency | 1 | 2018 | 16 | 0.150 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2020 | 183 | 0.150 |
Why?
|
Protein C Deficiency | 1 | 2017 | 25 | 0.150 |
Why?
|
Autoantibodies | 2 | 2024 | 2126 | 0.150 |
Why?
|
Cohort Studies | 6 | 2024 | 41800 | 0.150 |
Why?
|
Cisplatin | 1 | 2024 | 1661 | 0.150 |
Why?
|
Gene Frequency | 1 | 2024 | 3625 | 0.140 |
Why?
|
Genes, myc | 2 | 2008 | 391 | 0.140 |
Why?
|
Male | 18 | 2024 | 365249 | 0.140 |
Why?
|
Blood Platelets | 4 | 2020 | 2479 | 0.140 |
Why?
|
Platelet Aggregation | 2 | 2018 | 769 | 0.140 |
Why?
|
Models, Economic | 1 | 2021 | 721 | 0.140 |
Why?
|
Vasculitis | 1 | 2021 | 525 | 0.140 |
Why?
|
Endothelial Cells | 2 | 2020 | 3591 | 0.130 |
Why?
|
E-Selectin | 1 | 2018 | 578 | 0.130 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.130 |
Why?
|
Zinc | 1 | 2020 | 678 | 0.130 |
Why?
|
Endothelium | 1 | 2018 | 768 | 0.130 |
Why?
|
Middle Aged | 13 | 2024 | 223740 | 0.130 |
Why?
|
Female | 16 | 2024 | 397464 | 0.130 |
Why?
|
Aged | 10 | 2024 | 171790 | 0.120 |
Why?
|
Genetic Association Studies | 1 | 2024 | 2747 | 0.120 |
Why?
|
Early Diagnosis | 1 | 2020 | 1195 | 0.120 |
Why?
|
Thrombocytopenia | 1 | 2022 | 1181 | 0.120 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4568 | 0.120 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 1048 | 0.120 |
Why?
|
Risk Factors | 6 | 2024 | 74971 | 0.110 |
Why?
|
Titanium | 1 | 2017 | 495 | 0.110 |
Why?
|
Oncogenes | 2 | 2011 | 1236 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2021 | 13020 | 0.110 |
Why?
|
Aortic Aneurysm | 1 | 2018 | 649 | 0.110 |
Why?
|
Protein Folding | 1 | 2016 | 871 | 0.100 |
Why?
|
Macaca mulatta | 2 | 2017 | 2365 | 0.100 |
Why?
|
Gene Silencing | 2 | 2008 | 1505 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1936 | 0.100 |
Why?
|
Fibrin Fibrinogen Degradation Products | 3 | 2020 | 425 | 0.090 |
Why?
|
Fibrinolytic Agents | 1 | 2021 | 2080 | 0.090 |
Why?
|
Cost-Benefit Analysis | 2 | 2021 | 5544 | 0.090 |
Why?
|
Genotype | 2 | 2024 | 13048 | 0.090 |
Why?
|
Animals | 15 | 2024 | 169408 | 0.090 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6856 | 0.090 |
Why?
|
Endoplasmic Reticulum | 1 | 2016 | 1133 | 0.090 |
Why?
|
Heparin | 1 | 2017 | 1636 | 0.090 |
Why?
|
Recurrence | 2 | 2021 | 8512 | 0.090 |
Why?
|
Aorta | 1 | 2018 | 2046 | 0.090 |
Why?
|
Prostheses and Implants | 1 | 2017 | 1279 | 0.090 |
Why?
|
Perioperative Care | 1 | 2018 | 1045 | 0.090 |
Why?
|
Treatment Outcome | 4 | 2024 | 65485 | 0.090 |
Why?
|
Nitric Oxide | 1 | 2018 | 2149 | 0.080 |
Why?
|
Mice | 11 | 2024 | 82074 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2017 | 1397 | 0.080 |
Why?
|
Acute Disease | 1 | 2020 | 7245 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3814 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6546 | 0.080 |
Why?
|
Propensity Score | 1 | 2016 | 1968 | 0.080 |
Why?
|
Software | 1 | 2022 | 4480 | 0.080 |
Why?
|
Epilepsy | 1 | 2023 | 3326 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2018 | 1459 | 0.070 |
Why?
|
Electrocardiography | 1 | 2021 | 6413 | 0.070 |
Why?
|
Reoperation | 1 | 2018 | 4342 | 0.070 |
Why?
|
Plasma | 2 | 2022 | 585 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2024 | 81892 | 0.070 |
Why?
|
Phenotype | 1 | 2024 | 16735 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 9081 | 0.070 |
Why?
|
Genomics | 1 | 2022 | 5928 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 3626 | 0.070 |
Why?
|
Risk Assessment | 2 | 2024 | 24330 | 0.060 |
Why?
|
Length of Stay | 2 | 2021 | 6525 | 0.060 |
Why?
|
Prospective Studies | 2 | 2024 | 54950 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2016 | 3724 | 0.060 |
Why?
|
Fluorine Radioisotopes | 1 | 2008 | 424 | 0.060 |
Why?
|
Farnesol | 1 | 2005 | 20 | 0.060 |
Why?
|
Genes, ras | 1 | 2008 | 665 | 0.060 |
Why?
|
Erythrocyte Transfusion | 2 | 2021 | 575 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5716 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2024 | 16051 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2011 | 998 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12563 | 0.060 |
Why?
|
Prognosis | 3 | 2023 | 30044 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2023 | 26394 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5176 | 0.050 |
Why?
|
Lymphoma | 2 | 2011 | 1900 | 0.050 |
Why?
|
Osteosarcoma | 1 | 2008 | 911 | 0.050 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2023 | 97 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3116 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3239 | 0.050 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2023 | 146 | 0.050 |
Why?
|
Mice, Inbred C3H | 1 | 2023 | 915 | 0.050 |
Why?
|
Cell Shape | 1 | 2023 | 371 | 0.050 |
Why?
|
Models, Biological | 2 | 2017 | 9499 | 0.050 |
Why?
|
Blood Component Transfusion | 1 | 2022 | 141 | 0.050 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13593 | 0.050 |
Why?
|
Penetrance | 1 | 2023 | 386 | 0.050 |
Why?
|
Database Management Systems | 1 | 2022 | 263 | 0.050 |
Why?
|
ras Proteins | 1 | 2005 | 1058 | 0.040 |
Why?
|
Complement System Proteins | 1 | 2023 | 738 | 0.040 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2008 | 2056 | 0.040 |
Why?
|
Arterioles | 1 | 2020 | 252 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9756 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2011 | 3580 | 0.040 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 348 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 2008 | 1166 | 0.040 |
Why?
|
von Willebrand Factor | 1 | 2023 | 680 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 644 | 0.040 |
Why?
|
Decision Trees | 1 | 2021 | 509 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 855 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1917 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 640 | 0.040 |
Why?
|
Bone and Bones | 1 | 2008 | 2589 | 0.040 |
Why?
|
Computer Simulation | 1 | 2011 | 6289 | 0.040 |
Why?
|
Fibrin | 1 | 2020 | 514 | 0.040 |
Why?
|
Neoplasms | 2 | 2022 | 22390 | 0.040 |
Why?
|
Abdominal Muscles | 1 | 2018 | 172 | 0.040 |
Why?
|
Factor Xa | 1 | 2018 | 166 | 0.040 |
Why?
|
Platelet Count | 1 | 2020 | 787 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
Young Adult | 2 | 2021 | 60110 | 0.040 |
Why?
|
Factor VIIa | 1 | 2018 | 103 | 0.040 |
Why?
|
Markov Chains | 1 | 2021 | 979 | 0.040 |
Why?
|
Sulfhydryl Compounds | 1 | 2018 | 296 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2023 | 22381 | 0.030 |
Why?
|
Antithrombin III | 1 | 2017 | 128 | 0.030 |
Why?
|
Sarcoma | 1 | 2008 | 1806 | 0.030 |
Why?
|
Sternotomy | 1 | 2018 | 132 | 0.030 |
Why?
|
Alloys | 1 | 2017 | 111 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 878 | 0.030 |
Why?
|
Standard of Care | 1 | 2021 | 570 | 0.030 |
Why?
|
Mice, Transgenic | 4 | 2011 | 9564 | 0.030 |
Why?
|
Bone Neoplasms | 1 | 2008 | 2565 | 0.030 |
Why?
|
P-Selectin | 1 | 2018 | 599 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 1737 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2022 | 1758 | 0.030 |
Why?
|
Integrin beta3 | 1 | 2015 | 120 | 0.030 |
Why?
|
Infant | 1 | 2017 | 36541 | 0.030 |
Why?
|
Allosteric Regulation | 1 | 2016 | 424 | 0.030 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 395 | 0.030 |
Why?
|
Platelet Activation | 1 | 2018 | 644 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2023 | 20244 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2008 | 8664 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2007 | 3608 | 0.030 |
Why?
|
Child, Preschool | 1 | 2017 | 42684 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1887 | 0.030 |
Why?
|
Catalytic Domain | 1 | 2016 | 699 | 0.030 |
Why?
|
Protein Binding | 2 | 2016 | 9344 | 0.030 |
Why?
|
Adolescent | 2 | 2021 | 89247 | 0.030 |
Why?
|
Drug Costs | 1 | 2021 | 1198 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1629 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1893 | 0.030 |
Why?
|
Skull | 1 | 2017 | 830 | 0.030 |
Why?
|
Cesarean Section | 1 | 2020 | 1417 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1339 | 0.020 |
Why?
|
Disease Models, Animal | 4 | 2016 | 18366 | 0.020 |
Why?
|
Placenta | 1 | 2020 | 1721 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6320 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2008 | 6401 | 0.020 |
Why?
|
Computational Biology | 1 | 2022 | 3562 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2008 | 9442 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2015 | 2226 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2016 | 3775 | 0.020 |
Why?
|
Models, Animal | 1 | 2016 | 2123 | 0.020 |
Why?
|
Child | 1 | 2017 | 80969 | 0.020 |
Why?
|
Cell Membrane | 1 | 2018 | 3659 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8559 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2024 | 14485 | 0.020 |
Why?
|
Biocompatible Materials | 1 | 2017 | 1703 | 0.020 |
Why?
|
Reference Values | 1 | 2016 | 4941 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3858 | 0.020 |
Why?
|
Iron | 1 | 2017 | 1813 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7057 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4207 | 0.020 |
Why?
|
Aortic Valve | 1 | 2018 | 1969 | 0.020 |
Why?
|
Hepatitis C | 1 | 2018 | 1595 | 0.020 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2018 | 1568 | 0.020 |
Why?
|
Doxycycline | 1 | 2008 | 349 | 0.020 |
Why?
|
Bone Development | 1 | 2008 | 473 | 0.020 |
Why?
|
Quinazolines | 1 | 2011 | 1373 | 0.020 |
Why?
|
Salicylates | 1 | 2005 | 128 | 0.020 |
Why?
|
Respiratory Mucosa | 1 | 2008 | 439 | 0.010 |
Why?
|
Intraoperative Care | 1 | 2008 | 771 | 0.010 |
Why?
|
Blotting, Western | 1 | 2011 | 5035 | 0.010 |
Why?
|
California | 1 | 2008 | 1443 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6131 | 0.010 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1769 | 0.010 |
Why?
|
Cell Proliferation | 2 | 2011 | 10486 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2008 | 1793 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6085 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9384 | 0.010 |
Why?
|
Insulin | 1 | 2016 | 6610 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4478 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2008 | 3629 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10845 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8745 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 59738 | 0.010 |
Why?
|
Pregnancy | 1 | 2020 | 30175 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 6991 | 0.010 |
Why?
|
Neuroblastoma | 1 | 2005 | 1266 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9528 | 0.010 |
Why?
|
Survival Analysis | 1 | 2008 | 10115 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40266 | 0.010 |
Why?
|
Survival Rate | 1 | 2008 | 12873 | 0.010 |
Why?
|
Signal Transduction | 2 | 2007 | 23652 | 0.010 |
Why?
|
United States | 1 | 2021 | 73180 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2008 | 6673 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2008 | 11684 | 0.010 |
Why?
|
Incidence | 1 | 2008 | 21545 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 17174 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 13699 | 0.000 |
Why?
|